MedTrace Logo

MIVetsCan: Cannabidiol (CBD)-Care Trial

NCT06213233 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2025-05-21

No results posted yet for this study

Summary

This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.

Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.

The study hypotheses:

\- CBD would improve overall pain symptoms compared to placebo

Conditions

  • Pain, Chronic

Interventions

DRUG

Placebo

Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

DRUG

Cannabidiol

Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

Sponsors & Collaborators

  • Michigan, State of, Licensing and Regulatory Affairs

    collaborator UNKNOWN

  • Kevin Boehnke

    lead OTHER

Principal Investigators

  • Kevin Boehnke, PhD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06213233 on ClinicalTrials.gov